Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.24

€1.24

4.560%
0.054
4.560%
-
 
23.08.24 / Tradegate WKN: A12ETZ / Name: Coherus / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Coherus Bioscien. Stock

Coherus Bioscien. dominated the market today, gaining €0.054 (4.560%).
Our community identified positive and negative aspects for Coherus Bioscien. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Coherus Bioscien. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.

Pros and Cons of Coherus Bioscien. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Coherus Bioscien. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Coherus Bioscien. 4.560% 8.696% -18.879% -71.053% -59.293% -90.553% -93.737%
Evolus Inc 2.940% 16.667% 21.739% 64.706% 54.696% 51.351% -
Ardelyx Inc. 5.770% 6.941% 7.836% 67.751% -1.903% 364.754% 79.034%
Brainstorm Cell -2.990% 13.838% 1.480% -77.964% 36.504% -88.225% -90.377%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of Coherus Biosciences, a player in the Biotechnology & Medical Research sector, reflect a company struggling to find its footing in a fiercely competitive industry. With significant losses indicated across multiple financial metrics, it is clear that challenges abound. However, certain aspects do present opportunities for potential recovery and growth. This analysis delves into the various dimensions of Coherus' financial standing, highlighting both the strengths and weaknesses that define its current position.

Pros:

Market Capitalization and Target Price: Coherus holds a market capitalization of approximately $163 million, which can be seen as substantial for a biotech firm. Additionally, the Wall Street target price of $25.71 indicates optimistic projections from analysts, signaling potential upside for investors if the company can overcome its financial challenges.

Comments

Buy Coherus Bioscien.
Show more

Prediction Buy
Perf. (%) -42.76%
Target price 14.612
Change
Ends at 14.12.17

(Laufzeit überschritten)
Show more

Prediction Buy
Perf. (%) -42.76%
Target price 14.612
Change
Ends at 14.12.17

next up

Der Wert gelitten und sollte bald wieder zu seinem durchschnittlichen

Show more

News

Why Coherus Biosciences Stock Tumbled on Thursday: https://g.foolcdn.com/editorial/images/769378/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg
Why Coherus Biosciences Stock Tumbled on Thursday

The final set of results for Coherus Biosciences' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock